|Traded as||NASDAQ: ARWR|
Russell 2000 Component
|Christopher Anzalone, Ph.D., president and chief executive officer
Bruce Given, M.D., chief operating officerKen Myszkowski, MBA, CPA, chief financial officer
Arrowhead Pharmaceuticals is a publicly traded (NASDAQ: ARWR) biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for Hepatitis B, the liver disease associated with alpha 1-antitrypsin deficiency (AATD) and cardiovascular disease. The company has eight products in its pipeline, in various stages of development.
|ARO-HBV||Hepatitis B||In Clinic Phase 1/2||Partnered with Janssen|
|ARO-AAT||Alpha-1 Antirypsin Deficiency||In Clinic Phase 1/2||Orphan Drug Designation|
|ARO-APOC3||Hypertriglyceridemia||Pre-Clinical||Orphan Drug Designation|
|ARO-HIF2||Renal Cell Carcinoma||Pre-Clinical|
|ARO-ANG3||Dyslipidemia||Pre-Clinical||Orphan Drug Designation|
|AMG 890||Cardiovascular Disease||In Clinic Phase 1/2||Partnered with Amgen|
|ARO-AMG1||Undisclosed Cardiovascular||Pre-Clinical||Partnered with Amgen|
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018-- Arrowhead Pharmaceuticals Inc. closed on a $3.7 Billion License and Collaboration Agreements with Janssen to develop and commercialize ARO-HBV. As part of the overall deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.